RCM
CYTO

RA Capital Management’s Altamira Therapeutics Ltd CYTO Stock Holding History

RA Capital Management’s Portfolio CYTO Stock Details CYTO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-6
Closed -$1.67M – 49
2015
Q3 		$1.67M Sell
6
-6
-50% -$2.3M 0.24% 40
2015
Q2 		$4.57M Hold
12
– – 0.46% 35
2015
Q1 		$5.03M Hold
12
– – 0.5% 34
2014
Q4 		$3.67M Hold
12
– – 0.39% 32
2014
Q3 		$5.42M Buy
+12
New +$5.94M 0.64% 26

Other funds holding CYTO

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BAMS
Bellevue Asset Management (Switzerland) Kuesnacht, Switzerland $656M AUM 11.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CPCM
Clifton Park Capital Management Wilmington, Delaware $881M AUM 5.59% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
TAM
Tocqueville Asset Management New York $6.74B AUM 32.29% 1-Year Est. Return
HCM
Harvey Capital Management Palm Beach, Florida $439M AUM 37.68% 1-Year Est. Return
KeyBank National Association
KeyBank National Association Cleveland, Ohio $27.4B AUM 24.17% 1-Year Est. Return

RA Capital Management's CYTO Position: Q4 2015 in Review

RA Capital Management sold out of Altamira Therapeutics Ltd (CYTO) in Q4 2015, closing a stake of 6 shares — an estimated $1.67M sold.

RA Capital Management first reported a position in CYTO in Q3 2014 and held it in 5 quarters. The position peaked at $5.42M in Q3 2014. 10 funds tracked by Wall St. Rank hold CYTO as of Q4 2015.

  • RA Capital Management reported no remaining Altamira Therapeutics Ltd position as of Q4 2015 after selling out during the quarter.
  • RA Capital Management sold 6 Altamira Therapeutics Ltd shares in Q4 2015, an estimated $1.67M.
  • RA Capital Management first reported a position in Altamira Therapeutics Ltd in Q3 2014 and held it in 5 quarters.
  • RA Capital Management's Altamira Therapeutics Ltd position peaked at $5.42M in Q3 2014.
  • 10 funds tracked by Wall St. Rank held Altamira Therapeutics Ltd as of Q4 2015.

Based on RA Capital Management's 13F filing for Q4 2015, filed 16 Feb 2016.